The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1O745K     2-[ (3S,5S,6R,7S,8E,10R,11R,12Z,14 E)-6...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of nchembio790-comp21


High impact information on nchembio790-comp21


Analytical, diagnostic and therapeutic context of nchembio790-comp21


  1. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Ramanathan, R.K., Egorin, M.J., Eiseman, J.L., Ramalingam, S., Friedland, D., Agarwala, S.S., Ivy, S.P., Potter, D.M., Chatta, G., Zuhowski, E.G., Stoller, R.G., Naret, C., Guo, J., Belani, C.P. Clin. Cancer Res. (2007) [Pubmed]
  2. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Ronnen, E.A., Kondagunta, G.V., Ishill, N., Sweeney, S.M., Deluca, J.K., Schwartz, L., Bacik, J., Motzer, R.J. Investigational new drugs. (2006) [Pubmed]
  3. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Burger, A.M., Fiebig, H.H., Stinson, S.F., Sausville, E.A. Anticancer Drugs (2004) [Pubmed]
  4. In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation. Ochel, H.J., Gademann, G. Anticancer Res. (2006) [Pubmed]
  5. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Ramanathan, R.K., Trump, D.L., Eiseman, J.L., Belani, C.P., Agarwala, S.S., Zuhowski, E.G., Lan, J., Potter, D.M., Ivy, S.P., Ramalingam, S., Brufsky, A.M., Wong, M.K., Tutchko, S., Egorin, M.J. Clin. Cancer Res. (2005) [Pubmed]
  6. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Egorin, M.J., Lagattuta, T.F., Hamburger, D.R., Covey, J.M., White, K.D., Musser, S.M., Eiseman, J.L. Cancer Chemother. Pharmacol. (2002) [Pubmed]
  7. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Egorin, M.J., Zuhowski, E.G., Rosen, D.M., Sentz, D.L., Covey, J.M., Eiseman, J.L. Cancer Chemother. Pharmacol. (2001) [Pubmed]
  8. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. Xu, L., Eiseman, J.L., Egorin, M.J., D'Argenio, D.Z. Journal of pharmacokinetics and pharmacodynamics. (2003) [Pubmed]
  9. Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. Agnew, E.B., Wilson, R.H., Grem, J.L., Neckers, L., Bi, D., Takimoto, C.H. J. Chromatogr. B Biomed. Sci. Appl. (2001) [Pubmed]
  10. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Eiseman, J.L., Lan, J., Lagattuta, T.F., Hamburger, D.R., Joseph, E., Covey, J.M., Egorin, M.J. Cancer Chemother. Pharmacol. (2005) [Pubmed]
WikiGenes - Universities